I would say that 847 is excellent too. The conclusion statement is less dramatic, but the result statement should be headline news: "CYCART-19 T cells induced potent cytolytic activity against solid tumor cells infected with onCARlytics."
They were trialling it in human liver cancer - xenografted into (I assume) mice. And they saw a "potent" effect of their CAR-T in that solid tumour. That really is outstanding!
Apparently they also tried a more traditional CAR-T product "PBMC-derived CD19-CAR T cells." That would be a CAR-T derived from Human peripheral blood mononuclear cells (PBMCs). That trial showed "comparable anti-tumour activity" - ie when used against solid tumor cells infected with onCARlytics.
So OnCARlytics works really well with both.
The difference - they point out - is that their placenta derived CYCART-19 drug had a much lower CRS (Cytokine Release Syndrome) side effect. CRS (a massive inflammatory response) is the most common toxicity related to CAR-T treatment and can be fatal.
So they are saying that their results validate OnCARlytics, but also validate CYCART-19 as a superior form of CAR-T because (when used in combo with OnCARlytics) it has a similar "potent" effectiveness to the more standard CAR-T but with less toxicity.
That could be a huge winning combination for Celularity and for Imugene....
I am amazed there is still no ASX Announcement. 3 preclinical studies validating OnCARlytics as effective for CAR-T in solid tumours - preclinical, of course. Fabulous news.
(20min delay)